Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 14/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857442 | 1.00 | DAO (0.49) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL1781693 | 0.81 | RIPK1 (0.50) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL29587438 | 0.80 | RIPK1 (0.48) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL30376472 | 0.77 | RIPK1 (0.46) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL22430408 | 0.76 | RIPK1 (0.46) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL27984199 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL28256598 | 0.74 | NR3C1 (0.48) | DAORIPK1 | |
| SCHEMBL18511075 | 0.74 | RIPK1 (0.44) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL28300252 | 0.73 | RIPK1 (0.62) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL22537693 | 0.72 | RIPK1 (0.55) | DAORIPK1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| CN-110402248-B | Azaindoles as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2023-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | DAO 587/4885RIPK1 2340/4885CCNB2 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.